Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
, Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024 , at 4:30 p.
m. ET , to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2024 . To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call.
No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.
com . An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio TM (oral nalbuphine extended-release (ER)) for the treatment of chronic cough in idiopathic pulmonary fibrosis ( IPF ) and refractory chronic cough ( RCC ). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist ( KAMA ), .
